We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Genetic Mutation Causes High Bone Density

By Biotechdaily staff writers
Posted on 29 May 2002
Print article
Researchers have discovered a genetic mutation that causes extremely high bone density in humans. The finding may suggest a new route for developing drugs that can increase bone density to prevent or treat osteoporosis. The study was published in the May 16, 2002, issue of The New England Journal of Medicine.

The investigators identified a US family with very strong bones because of a genetic mutation. Family members with this mutation have no symptoms, but they do have a strikingly deep and wide jaw and bony growth on the palate. Twenty family members aided the research by providing blood samples for DNA and bone density testing. Seven members of the family had extremely high bone density, while nine had entirely normal density. Serum and urinary biochemical measurements were performed in four members and then compared with results from nine control subjects.

"What we found is that the high bone density in this family behaved as a single gene disorder,” said Richard Lifton, M.D., chair of the department of genetics at Yale School of Medicine (New Haven, CT, USA). "We then went on to map the location of the gene and identified the specific mutation responsible for the high bone density.”

The researchers mapped the gene to the same chromosome segment in LRP5, shown to be the source of a mutation that causes a loss in the function of the LRP5 gene, resulting in low bone density. "It made us wonder if a different mutation increased LRP5 function leading to an opposite phenotype, that is, high bone density,” explained Dr. Lifton. He noted that the study also showed that prevention of the normal inhibition of LRP5 by Dkk, another developmental protein, causes high bone density without other clinical side effects, suggesting a new route for osteoporosis therapy.




Related Links:
Yale Univ.
Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAb Immunoassay
Chorus TRAb
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.